AXIS Participaciones Empresariales
VC Fund
Madrid, Spain
AXIS Participaciones Empresariales is a VC fund in Madrid focused on Health Care and Biotechnology. One of the sector's most longstanding operators, Axis Participaciones Empresariales, Sociedad Gestora de Entidades de Capital Riesgo S.A. was established in 1986 on the initiative of State-owned banking officials for the purpose of boosting venture capital activity in Spain. Since 1993, it has been wholly owned by Instituto de Crédito Oficial(ICO).
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries AXIS Participaciones Empresariales invests in
Stages AXIS Participaciones Empresariales invests in
Countries AXIS Participaciones Empresariales invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Joaquín Simón Sebastián
|
|||
Mercedes Storch
|
|||
|
Rosario Nistal Murillo
|
|||
Investment Focus
Industry
- Health Care 2 (20%)
- Biotechnology 2 (20%)
- Mobile 1 (10%)
- Fitness 1 (10%)
- Medical 1 (10%)
Stage
- Venture - Series Unknown 3 (30%)
- Series B 2 (20%)
- Funding Round 2 (20%)
- Seed 1 (10%)
- Series A 1 (10%)
Country
- Spain 6 (60%)
- Mexico 1 (10%)
- Germany 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joaquín Simón Sebastián
Operations Manager
|
Operations Manager | Total investments: 0 | Find email | |
|
Mercedes Storch
Head Of International Relations
|
Head Of International Relations | Total investments: 0 | Find email | |
|
Rosario Nistal Murillo
Investment Chief
|
Investment Chief | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xoople
|
Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface. | $25.1M / Venture - Series Unknown / Jul 30, 2025 | |
|
Xoople
|
Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface. | $128.6M / May 14, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Vivira
|
Vivira Health Lab focuses on making physical rehab programs available to everyone. | Venture - Series Unknown / Oct 14, 2024 | |
Cabify
|
Cabify is a ride-sharing company that connects private users and companies with the forms of transport that suit their needs.At Cabify, they make sure their customers - passengers and drivers - enjoy the ride. Charging a fair price, improving your door-to-door journey, and making transport accessible to all are just some of the things they thinkare important. Why? Because they believe that by making transport better, they can make their cities and communities better.Founded in 2011, the company is headquartered in Madrid, Madrid, Spain. | $65M / Venture - Series Unknown / Mar 28, 2023 | |
|
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $12.7M / Series B / Oct 20, 2022 | |
Qilimanjaro Quantum Tech
|
Qilimanjaro is a quantum computing company based in Barcelona, making quantum useful today. Founded in 2019, we develop full-stack quantum computers based on fluxonium analog qubits, a novel architecture that bypasses the need for error correction, enabling faster, more scalable solutions. Our approach is application-first: analog quantum computingoffers near-term advantages and optimality for highly relevant problems, especially in simulation, optimization, and AI, where digital QPUs fall short. We follow a dual strategy to democratize access to quantum computing:• Via our Quantum-as-a-Service (QaaS) platform, users can remotely access our hybrid quantum data centers, combining analog and digital QPUs with classical HPC. • For research institutions and HPC centers, we provide on-premise quantum deployments, offering flexibility, control, and co-design.By aligning quantum hardware with real-world needs, Qilimanjaro is building a future where quantum computing is practical, scalable, and ready to deliver value - not in decades, but now. | $1.2M / Seed / Aug 04, 2022 | |
SATLANTIS
|
SATLANTIS designs and manufactures high performance Earth observation payloads for small satellites.SATLANTIS is a company based in Spain and Florida (USA) that aims to connect the three vertices of the “triangle of knowledge” –universities, industries, and government agencies– to work together towards a common goal: to become a global leader inthe use of constellation of microsatellites for scientific and commercial applications.SATLANTIS' premier product is iSIM, an “Integrated Standard Imager for Earth Observation Microsatellites”. An optical imaging product family for micro satellites (20-75 kg) that will provide an unparalleled performance and and flexibility for a fraction of the cost of today's Earth Observation instruments. The company is also closing alliances with partners in the US and Europe to develop the infrastructure for manufacture, integration, launch, and operations of standardized microsatellites. | $2.7M / Series A / Nov 07, 2016 | |
Oncovision
|
Oncovision (GEM Imaging S.A.) is a Spanish technologic start-up company created in 2003 with the initiative of the Corpuscular Physics Institute (CSIC) and the University of Valencia.They work in Molecular Vision applied to Health Sciences focusing in: cancer diagnosis and treatment, and advanced research in neurology, oncology, and cardiology.They are a company focused on Molecular Vision, which creates, develops and markets new medical technologies, global innovations with relevant clinical and economic advantages, often representing a breakthrough in current standards of diagnosis and treatment.ONCOVISION´s original, fresh technology, strong intellectual property, top-level clinical evidence, leading global reference centers, and pioneering protocols, is supported by its dynamic cross-functional team. ONCOVISION is opening unprecedented options in the treatment of cancer and serious cardiac and neurological diseases.Their team and the company’s technologies have been recognized by Spanish and European prestigious institutions. In 2007, the company was selected as one of the “20 Best Technologic Companies in Spain” and won the “National Medical Physics 2007 Congress Award” In 2008, it was one of the “20 Best Health Technology Companies in Europe” by the prestigious European Technology Tour, as well as finalist in the “National 25th Aniversary Enisa Award” Prof. Jose María Benlloch, active member of the company, won in 2008, the well-known “Jaime I” award. Scientists, technicians, and technologists of ONCOVISION have dozens of publications and presentations at scientific and medical conferences worldwide.Their shareholding, based in Valencia, was strengthened in August 2006 by the Spanish venture capital firm Bullnet, unifying its proven track in technological and management capabilities with companies in Spain and Portugal. The company is managed by a multi-task professional team with international experience.With proven clinical and scientific results, differentiated technology with enormous potential for future technological and financial capacity, intellectual property and developing lines, ONCOVISION is today ahead in the Spanish and European Health Industry. | $3.3M / Sep 12, 2012 | |
Bionostra
|
It is one of the largest companies in the Spanish biotechnology sector. Its activity focuses on research, development and commercialization of biotechnology services. Born in 2000 under the initiative of a group of researchers of the Higher Council for Scientific Research (CSIC) and business professionals and is one of four companies in thebusiness group Bionostra. | $2.4M / Series B / Oct 14, 2005 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does AXIS Participaciones Empresariales invest in?
AXIS Participaciones Empresariales invests primarily in Health Care, Biotechnology and Mobile startups, most often at Venture - Series Unknown and Series B stage. Most of the 10 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AXIS Participaciones Empresariales?
Public channels for AXIS Participaciones Empresariales include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AXIS Participaciones Empresariales?
The team at AXIS Participaciones Empresariales includes Joaquín Simón Sebastián (Operations Manager), Mercedes Storch (Head Of International Relations) and Rosario Nistal Murillo (Investment Chief). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
